vimarsana.com

Page 8 - மைய மருந்து தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vaccine: DCGI panel to meet Bharat Biotech officials shortly

Vaccine: DCGI panel to meet Bharat Biotech officials shortly ​ By IANS | Published on ​ Sat, Jan 2 2021 12:36 IST | ​ 0 Views Vaccine: DCGI panel to meet Bharat Biotech officials shortly. Image Source: IANS News New Delhi, Jan 2 : A committee of experts assessing the coronavirus vaccines has called Hyderabad-based Bharat Biotech for a meeting at 1.30 pm on Saturday, a day after the firm was asked to present more data on its Covaxin to get the go-ahead, a top source said. On Friday, the Subject Expert Committee of the Central Drug Standard Control Organisation (CDSCO) had held that the data provided by Bharat Biotech for its coronavirus vaccine was not sufficient for the grant of approval for emergency use and sought more information.

Welcome To IANS Live - LatestNews - After Covishield , expert panel recommends Bharat Biotech s Covaxin for emergency use

Photo Credit: IANS IANSLive New Delhi, Jan 2 (IANS) The Subject Expert Committee of Central Drug Standard Control Organization on Saturday recommended Bharat Biotech s Covaxin for emergency use in India. The final decision on its approval will, however, be taken by the Drug Controller General of India (DCGI). To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 02-January-2021

Does India have the doses to fulfil Phase1 Covid vaccine goals

URL copied A health worker gets a shot of the vaccine. (Representational image) Given that India has set the goal of vaccinating 30 crore people with Covid-19 jabs by July, can the country procure enough doses to fulfill that goal? To vaccinate 30 crore people, the country will need 60 crore doses as the two vaccines that are leading the race to get approval from the government require two-doses per person for protection. These two vaccines that the government is currently considering giving the approval are Covishield and Covaxin . While the Pune-based Serum Institute of India has partnered with Oxford-AstraZeneca for conducting clinical trials and manufacturing Covishield , Bharat Biotech has collaborated with the Indian Council of Medical Research (ICMR) for Covaxin .

After Covishield , expert panel recommends Bharat Biotech s Covaxin for emergency use

New Delhi: The Subject Expert Committee of Central Drug Standard Control Organization Saturday recommended Bharat Biotech’s ‘Covaxin’ for emergency use in India. The final decision on its approval will, however, be taken by the Drug Controller General of India (DCGI). The committee of experts assessing Coronavirus vaccines had called Hyderabad-based Bharat Biotech for a meeting in the afternoon today, a day after the firm was asked to present more data to get a nod, a top source said Saturday. Friday, the Subject Expert Committee of the Central Drug Standard Control Organisation (CDSCO) had held that the data provided by Bharat Biotech for its Coronavirus vaccine is not sufficient for grant of emergency use approval and asked for more information.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.